Chevy Chase, MD, United States of America

Nicholas P Restifo

This inventor holds 27 USPTO granted patents and 15 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Cell Therapy Techniques. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Intima Bioscience, Inc., Regents of the University of Minnesota. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas P Restifo. Retrieved from https://idiyas.com/inventor/nicholas-p-restifo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 15)

% Patents Active = 85.2

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 4.3

ph-index = 9

Forward Citations = 178(Granted Patents)

Location History:

Washington, DC (US) (1998 - 2011)
Bethesda, MD (US) (2023)
Chevy Chase, MD (US) (2012 - 2024)

Company Filing History:

24 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

10 out of 15

Intima Bioscience, Inc.

patents

10 out of 2,372

Regents of the University of Minnesota

patents

4. 2 out of 1,217

The United States of America as Represented by the Department of Health

patents

5. 1 out of 537

Icahn School of Medicine at Mount Sinai

The Government of the United States of America, as Represented by the

patents

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

T Memory Stem Cells

Thymic Emigrant Cells

Hematopoietic Progenitor Cells

Intracellular Genomic Transplant

Tumor Infiltrating Lymphocytes

T Cell Therapy

Immunogenic Chimeras

GP100-Specific T Cell Receptors

Recombinant Influenza Viruses

Therapy Selection Methods

Pluripotent Stem Cells

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516289 - Methods of producing T memory stem cell populations (2026-01-06),

2. 12415845 - Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof (2025-09-16),

3. 12215349 - Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same (2025-02-04),

4. 12037607 - Methods of preparing hematopoietic progenitor cells in vitro (2024-07-16),

5. 11903966 - Intracellular genomic transplant and methods of therapy (2024-02-20),

6. 11898166 - In vitro generation of thymic organoid from human pluripotent stem cells (2024-02-13),

7. 11723923 - Methods of preparing T cells for T cell therapy (2023-08-15),

8. 11642375 - Intracellular genomic transplant and methods of therapy (2023-05-09),

9. 11642374 - Intracellular genomic transplant and methods of therapy (2023-05-09),

10. 11583556 - Modified cells and methods of therapy (2023-02-21),

11. 11312998 - Methods for selecting therapy for a cancer patient (2022-04-26),

12. 11266692 - Intracellular genomic transplant and methods of therapy (2022-03-08),

13. 11154574 - Tumor infiltrating lymphocytes and methods of therapy (2021-10-26),

14. 11147837 - Modified cells and methods of therapy (2021-10-19),

15. 11111478 - Methods of producing T memory stem cell populations (2021-09-07),

Title: Innovations in Cellular Therapies: The Contributions of Nicholas P. Restifo

Introduction

Nicholas P. Restifo is a distinguished inventor based in Chevy Chase, MD, renowned for his significant contributions to the field of cellular therapies. With a portfolio of 25 patents, Restifo has pioneered advancements that hold the potential to transform treatment methodologies in the biomedical field.

Latest Patents

Among his latest innovations are two pivotal patents focused on advancing cellular therapies. The first patent, titled "Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using the same," discloses methods for preparing thymic emigrant cells in vitro. This patent highlights the isolation of these cells and their potential use in pharmaceutical compositions aimed at treating conditions in mammals. The second patent, "Methods of preparing hematopoietic progenitor cells in vitro," articulates methods for producing CD34+CD43+ hematopoietic progenitor cells and outlines their differentiation to hematopoietic lineage cells. Both patents underscore Restifo's dedication to addressing significant health challenges, including cancer treatment.

Career Highlights

Restifo's illustrious career includes engagements with esteemed institutions such as the United States Department of Health and Human Services and the University of Minnesota. His work within these organizations has facilitated research and innovation aimed at enhancing therapeutic options for various ailments. His 25 patents reflect his commitment to pushing the boundaries of current scientific understanding and clinical application.

Collaborations

Throughout his career, Nicholas P. Restifo has collaborated with notable figures in the field, including Steven A. Rosenberg and Branden Moriarity. These collaborations have enabled the exchange of ideas and expertise, contributing to the advanced methodologies and treatments that Restifo has pioneered. Such partnerships are crucial in the ever-evolving landscape of biomedical research.

Conclusion

Nicholas P. Restifo stands out as an influential inventor dedicated to the betterment of medical treatments through innovative cellular therapies. His extensive patent portfolio and collaborative efforts demonstrate his commitment to improving healthcare outcomes. As the landscape of biomedical innovation continues to expand, Restifo's work will undoubtedly play a vital role in shaping the future of therapeutic approaches.

Profile summary based on public USPTO records.